देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
SALMETEROL (SALMETEROL XINAFOATE)
GLAXOSMITHKLINE INC
R03AC12
SALMETEROL
25MCG
METERED-DOSE AEROSOL
SALMETEROL (SALMETEROL XINAFOATE) 25MCG
INHALATION
60/120 DOSES
Prescription
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0126960001; AHFS:
CANCELLED POST MARKET
2006-07-12
_DCTM/201/540/2006-03-01-131-pm-pristine-serevent.doc _ _ _ _ _ _Page 1 of 50_ PRODUCT MONOGRAPH Pr SEREVENT ® salmeterol xinafoate inhalation aerosol 25 mcg salmeterol (as the xinafoate salt)/metered dose Pr SEREVENT ® DISKHALER ® Disk salmeterol xinafoate dry powder for inhalation 50 mcg salmeterol (as the xinafoate salt)/blister Pr SEREVENT ® DISKUS ® salmeterol xinafoate dry powder for inhalation 50 mcg salmeterol (as the xinafoate salt)/blister Bronchodilator (β 2 -adrenergic stimulant) GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 www.gsk.ca Date of Preparation: August 27, 2001 Date of Revision: March 2, 2006 Submission Control No: 102588 _©_ _ 2006 GlaxoSmithKline Inc. All Rights Reserved_ _ _ _®_ _SEREVENT, DISKHALER and DISKUS are registered trademarks, used under license by GlaxoSmithKline Inc. _ _DCTM/201/540/2006-03-01-131-pm-pristine-serevent.doc _ _ _ _ _ _Page 2 of 50_ Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS..................................................................................5 ADVERSE REACTIONS..................................................................................................11 DRUG INTERACTIONS ..................................................................................................16 DOSAGE AND ADMINISTRATION..............................................................................17 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................20 पूरा दस्तावेज़ पढ़ें